Clinical Trial Update: A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease [Phase 4]

View source ↗

Summary

Phase 4 noninferiority trial evaluating alglucosidase alfa manufactured at 160 L vs 4000 L scales in treatment-naïve infants with Pompe disease; the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Drugs mentioned

• Alglucosidase alfa (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease (Infantile-Onset), Glycogen Storage Disease Type II (GSD II) | Phase 4 | Status: TERMINATED | Results posted: 2016-01-18